Company intelligence / Profile preview

SeQure Dx

Waltham, Massachusetts, United States

Ownership: Private
Development stage: Other

Overview

SeQure Dx provides gene editing safety assessment tools and companion diagnostics to biopharma, specializing in comprehensive off-target risk profiling using ONE-seq and GUIDE-seq; enables drug developers to generate IND-enabling safety and editing data packages critical for regulatory submissions and patient safety throughout development and commercialization.

Therapeutic areas: Other
Modalities: Gene therapyCell therapyCRISPR-based therapy
Industry: Molecular Diagnostics

Partnerships

Biopharma partnerships (no specific companies named)now part of MaxCyte’s offerings

Beyond the preview

Go deeper on SeQure Dx.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SeQure Dx.

Explore the full profile